BMC Cancer 2020 Jun 1
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
Related Questions
Further radioligand therapy upon disease progression? If proceeding with further RLT, how many cycles may be planned?
This question is part o...
New answer by Radiation Oncologist at David Geffen School of Medicine at UCLA (September 28, 2025)
I believe this randomized trial does provide high-level evidence that adding 177Lu-PNT2002 prior to SBRT improves PFS compared with SBRT alone. If it were available off trial,...